Allergy & Immunology
Study | Removal of thymus in adults linked to increased death, cancer incidence
4 Aug, 2023 | 12:09h | UTCHealth Consequences of Thymus Removal in Adults – New England Journal of Medicine (link to abstract – $ for full-text)
Commentaries:
Doctors have long considered the thymus expendable. But could removing it be fatal? – Science
The thymus withers away after puberty. But it may be important for adults – Science News
Thymus gland critical for adult health, study finds – News Medical
Commentary on Twitter
In a study by Kooshesh et al., mortality, the risk of cancer, and levels of proinflammatory cytokines were higher among adults whose thymus had been removed than among control patients. Read the full study results: https://t.co/poaAiELsKG
— NEJM (@NEJM) August 2, 2023
Review | Autoimmunity and postural orthostatic tachycardia syndrome: Implications in diagnosis and management
4 Aug, 2023 | 11:49h | UTC
RCT | Maternal egg intake in early neonatal period does not impact infant egg allergy risk
2 Aug, 2023 | 13:47h | UTCSee also: Visual Abstract
An ESPGHAN position paper on the diagnosis, management and prevention of cow’s milk allergy
31 Jul, 2023 | 14:28h | UTC
Systematic Review | Medical treatment of eosinophilic esophagitis
21 Jul, 2023 | 13:27h | UTCMedical treatment of eosinophilic esophagitis – Cochrane Library
Summary: Medical treatments for eosinophilic esophagitis – Cochrane Library
Related:
M-A | Efficacy of elimination diets in eosinophilic esophagitis
RCT | Dupilumab in adults and adolescents with eosinophilic esophagitis
RCT | Direct oral challenge noninferior to skin testing followed by direct oral challenge in low-risk penicillin allergy patients
18 Jul, 2023 | 13:54h | UTCEfficacy of a Clinical Decision Rule to Enable Direct Oral Challenge in Patients With Low-Risk Penicillin Allergy: The PALACE Randomized Clinical Trial – JAMA Internal Medicine (free for a limited period)
See also: Visual Abstract
News Release: World-first clinical trial to help millions with penicillin allergies – Vanderbilt University Medical Center
Commentary: Trial supports use of direct oral challenge for penicillin allergy – CIDRAP
Guideline | Antibiotic therapy in patients with suspected antibiotic allergy
17 Jul, 2023 | 13:59h | UTC
Guidelines | Management of atopic dermatitis in adults with topical therapies
14 Jul, 2023 | 12:48h | UTC
Impact of newborn screening on severe combined immunodeficiency survival: results from a 36-year longitudinal study
14 Jul, 2023 | 12:45h | UTCMeasuring the effect of newborn screening on survival after haematopoietic cell transplantation for severe combined immunodeficiency: a 36-year longitudinal study from the Primary Immune Deficiency Treatment Consortium – The Lancet (link to abstract – $ for full-text)
Commentary on Twitter
Findings from a 36-year longitudinal study provide direct evidence that newborn screening for SCID has been the primary driver of improved survival in new-born babies in the USA and Canada since 2010.
Read the full article: https://t.co/TAAcPztpF9 pic.twitter.com/cOxvNNJmb9
— The Lancet (@TheLancet) July 12, 2023
Review | Hypereosinophilic syndrome (HES) and eosinophilic granulomatosis with polyangiitis (EGPA): two sides of the same coin
7 Jul, 2023 | 16:01h | UTCHES and EGPA: Two Sides of the Same Coin – Mayo Clinic Proceedings
Podcast | Wisely ordering autoantibodies
28 Jun, 2023 | 13:09h | UTC#399 Wisely Ordering Autoantibodies – ACP IM2023 – The Curbsiders
Adrenaline auto-injector prescription for patients at risk of anaphylaxis: BSACI guidance for primary care
6 Jun, 2023 | 14:28h | UTC
RCT | Dupilumab improves lung function and reduces exacerbations in COPD patients with elevated eosinophils
1 Jun, 2023 | 12:20h | UTCDupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil Counts – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary: Dupilumab Improves Outcomes for COPD, Type 2 Inflammation in Randomized Trial – HCP Live
Commentary on Twitter
Presented at #ATS2023: In the BOREAS trial, dupilumab resulted in a lower annualized rate of exacerbations than placebo among patients with COPD and an elevated blood eosinophil count. Full trial results: https://t.co/9IWZr3YqsN
— NEJM (@NEJM) May 21, 2023
Guideline | Investigation and management of acute transfusion reactions
29 May, 2023 | 11:02h | UTC
RCT | Peanut patch therapy is effective in desensitizing young children with allergies, but raises risk of serious adverse events
15 May, 2023 | 13:10h | UTCPhase 3 Trial of Epicutaneous Immunotherapy in Toddlers with Peanut Allergy – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary on Twitter
In the phase 3 EPITOPE trial involving children 1 to 3 years of age with peanut allergy, epicutaneous immunotherapy by means of a peanut patch was superior to placebo in desensitizing children to peanut. https://t.co/USk6HBI9Qh#pediatrics
— NEJM (@NEJM) May 10, 2023
Cohort Study | Autoimmune disorders’ incidence, prevalence & co-occurrence by age, sex, and socioeconomic status
8 May, 2023 | 13:14h | UTCIncidence, prevalence, and co-occurrence of autoimmune disorders over time and by age, sex, and socioeconomic status: a population-based cohort study of 22 million individuals in the UK – The Lancet (free for a limited period)
Commentary from the author on Twitter (thread – click for more)
Our latest research is out in @TheLancet today
We sought to answer:
1. Are autoimmune diseases on the rise as has been suggested?
2. Can we identify clues as to their causes (genetic or environmental)?
3. Do different autoimmune diseases cluster together & what might this mean? pic.twitter.com/noCpPpo8FU— Nathalie Conrad (@nathalie_conrad) May 6, 2023
Cohort Study | Idiopathic CD4 Lymphocytopenia linked to increased infection risk and cancer prevalence
5 May, 2023 | 15:16h | UTCReappraisal of Idiopathic CD4 Lymphocytopenia at 30 Years – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary on Twitter
Idiopathic CD4 lymphocytopenia was initially described approximately 30 years ago as #HIV infections were emerging. In this report, longer-term characteristics of this syndrome are described. https://t.co/kV45SKmRQv#InfectiousDisease
— NEJM (@NEJM) May 3, 2023
RCT | Efficacy and safety of tralokinumab in adolescents with moderate to severe atopic dermatitis
3 May, 2023 | 15:04h | UTCCommentary: Tralokinumab Efficacious, Well-Tolerated for Adolescents with Atopic Dermatitis – HCP Live
Commentary on Twitter
The ECZTRA 6 trial showed that targeted IL-13 inhibition with tralokinumab was efficacious and well tolerated in adolescents with moderate-to-severe AD, suggesting that it is a valuable treatment option in this age group. https://t.co/h36BW4XThE
— JAMA Dermatology (@JAMADerm) April 19, 2023
Immediate hypersensitivity reactions to antineoplastic agents – A practical guide for the oncologist
24 Apr, 2023 | 13:40h | UTCImmediate hypersensitivity reactions to antineoplastic agents – A practical guide for the oncologist- Cancer Treatment Reviews (free for a limited period)
See Tweet from one of the authors with infographic and link to free full text here
Identifying perioperative anaphylaxis in Japan: epidemiology, allergens, and diagnostic tools
17 Apr, 2023 | 13:10h | UTC
M-A | Timing of allergenic food introduction and risk of immunoglobulin E–mediated food allergy
11 Apr, 2023 | 14:32h | UTCNews Release: Earlier introduction of allergenic foods in children may prevent food allergies – Imperial College London
Commentary: Allergenic Food Introduction Led to Fewer Allergies, Higher Withdrawal Rate from Intervention – HCP Live
Related:
AAP Updated Recommendations for Dietary Interventions to Prevent Atopic Disease
Timing of introduction of allergenic solids for infants at high risk – Canadian Paediatric Society
Commentary on Twitter
In this study, earlier introduction of multiple allergenic foods was associated with a reduced risk of food allergy but with significant rates of withdrawal from the intervention. https://t.co/lZFkQIH9q7
— JAMA Pediatrics (@JAMAPediatrics) March 27, 2023
RCT | Baricitinib + topical corticosteroids effective in kids with moderate-severe atopic dermatitis
4 Apr, 2023 | 13:39h | UTC
Cohort Study | Associations between fetal or infancy pet exposure and food allergies
3 Apr, 2023 | 13:26h | UTC
RCT | Efficacy and safety of garadacimab, a factor XIIa inhibitor for hereditary angioedema prevention
31 Mar, 2023 | 13:26h | UTCEfficacy and safety of garadacimab, a factor XIIa inhibitor for hereditary angioedema prevention (VANGUARD): a global, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial – The Lancet (link to abstract – $ for full-text)
Commentary on Twitter (thread – click for more)
Hereditary angioedema is a rare disease associated with unpredictable, recurrent angioedema attacks that can be life-threatening.
New study data support the use of garadacimab as a potential prophylactic therapy in adolescents and adults: https://t.co/xlxoA3J3sh 🧵 pic.twitter.com/VqCOHnaQAp
— The Lancet (@TheLancet) March 6, 2023
Two phase 3 trials of lebrikizumab for moderate-to-severe atopic dermatitis
21 Mar, 2023 | 13:23h | UTCTwo Phase 3 Trials of Lebrikizumab for Moderate-to-Severe Atopic Dermatitis – New England Journal of Medicine (link to abstract – $ for full-text)
News Release: Largest study to date of lebrikizumab supports its use for treatment of atopic dermatitis – George Washington University
Commentary: Lebrikizumab Effective for Adults, Teens With Atopic Dermatitis – HealthDay